CAR-T: A Promising Treatment Method for Leukemia and Lymphoma
Leukemia is sometimes referred to as "blood cancer" and is the most common malignant disease. The symptoms of the disease can be aggressive and may not respond to conventional treatments such as chemotherapy or radiation therapy. Fortunately, to this day, efforts to find new methods of effective treatment continue.
One such method is called CAR-T and is available at the Ichilov Clinic.
How CAR-T Treatment Works
CAR-T therapy for leukemia is an innovative technique that uses the patient's own immune cells to seek out and destroy cancer cells.
After taking a blood sample from the patient, T-lymphocytes (a type of immune cell) are isolated. The lymphocytes are then modified to activate the synthesis of proteins that recognize malignant cells (chimeric antigen receptors CAR). After multiplying in laboratory conditions, the individually grown cell culture is introduced to the patient. Prior to this, the patient undergoes a preparatory chemotherapy course that helps CAR-T cells accurately recognize and destroy tumor clones.
Send your records — an Ichilov physician will reply within 1–2 days, free of charge.
Who Can Receive CAR-T Treatment/Indications for Use
It is necessary to undergo at least 2 courses of leukemia treatment beforehand. The duration of hospitalization for CAR-T therapy is determined individually, but on average, it lasts 2 weeks.
The best results with CAR-T can be achieved in young patients. Below are the results for achieving complete recovery/remission with CAR-T therapy: 85-90% in young children, approximately 80% in adolescents, and around 70% across all patient groups.
Tel Aviv Medical Center as an Expert Center for Providing CAR-T Treatment
- The Hematology Department at Ichilov has extensive experience in the most modern treatment methods for leukemia, lymphoma, and bone marrow transplantation.
- The team of hematologists at Ichilov has specialized in CAR-T treatment for three years and has experience in managing potential side effects.
- The Hematology Department at Ichilov was the first medical institution outside the United States to participate in research trials for treatment and the first to receive permission from authorities for the commercial use of T-cell therapy.
If you have loved ones suffering from leukemia, contact us right now. We will be happy to answer all your questions and strive to provide maximum assistance by all possible means.